Midatech and MonoSol create JV to take diabetes therapies forward
This article was originally published in Scrip
Executive Summary
A strategic joint venture, MidaSol Therapeutics, has been launched by UK nanomedicine company Midatech and its partner, the US drug delivery firm MonoSol Rx, aimed at commercialising diabetes therapies jointly developed by the companies.